WO2004098578A3 - Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517 - Google Patents

Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517 Download PDF

Info

Publication number
WO2004098578A3
WO2004098578A3 PCT/EP2004/050750 EP2004050750W WO2004098578A3 WO 2004098578 A3 WO2004098578 A3 WO 2004098578A3 EP 2004050750 W EP2004050750 W EP 2004050750W WO 2004098578 A3 WO2004098578 A3 WO 2004098578A3
Authority
WO
WIPO (PCT)
Prior art keywords
cdp870
adalimumab
infliximab
cdp517
alfa
Prior art date
Application number
PCT/EP2004/050750
Other languages
French (fr)
Other versions
WO2004098578A2 (en
Inventor
Johannes Barsig
Christian Weimar
Original Assignee
Altana Pharma Ag
Johannes Barsig
Christian Weimar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag, Johannes Barsig, Christian Weimar filed Critical Altana Pharma Ag
Publication of WO2004098578A2 publication Critical patent/WO2004098578A2/en
Publication of WO2004098578A3 publication Critical patent/WO2004098578A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the combined administration of a PDE4 inhibitor and a TNFα antagonist selected from the group consisting of infliximab, adalimumab, cdp870 and cdp571 for the treatment of a disease in which phosphodiesterase 4 (PDE4) and/or tumor necrosis factor alpha (TNFα) activity is detrimental.
PCT/EP2004/050750 2003-05-12 2004-05-10 Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517 WO2004098578A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03010593.6 2003-05-12
EP03010593 2003-05-12

Publications (2)

Publication Number Publication Date
WO2004098578A2 WO2004098578A2 (en) 2004-11-18
WO2004098578A3 true WO2004098578A3 (en) 2004-12-29

Family

ID=33427055

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/050750 WO2004098578A2 (en) 2003-05-12 2004-05-10 Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517

Country Status (1)

Country Link
WO (1) WO2004098578A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2738179A1 (en) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
ME01648B (en) * 2006-07-05 2014-09-20 Nycomed Gmbh Combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019749A1 (en) * 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
EP0626389A1 (en) * 1990-12-21 1994-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNF-alpha
WO1997029131A1 (en) * 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
WO1999055696A1 (en) * 1998-04-28 1999-11-04 Arzneimittelwerk Dresden Gmbh New hydroxyindoles, their use as phosphodiesterase 4 inhibitors and method for producing same
WO2001094585A1 (en) * 2000-06-06 2001-12-13 Celltech R & D Limited Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof
WO2002064584A1 (en) * 2001-02-15 2002-08-22 Altana Pharma Ag Phthalayinone-piperidino-derivatives as pde4 inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0626389A1 (en) * 1990-12-21 1994-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNF-alpha
WO1993019749A1 (en) * 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
WO1997029131A1 (en) * 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
WO1999055696A1 (en) * 1998-04-28 1999-11-04 Arzneimittelwerk Dresden Gmbh New hydroxyindoles, their use as phosphodiesterase 4 inhibitors and method for producing same
WO2001094585A1 (en) * 2000-06-06 2001-12-13 Celltech R & D Limited Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof
WO2002064584A1 (en) * 2001-02-15 2002-08-22 Altana Pharma Ag Phthalayinone-piperidino-derivatives as pde4 inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
TAYLOR P C: "ANTI-TNF THERAPY FOR RHEUMATOID ARTHRITIS AND OTHER INFLAMMATORY DISEASES", MOLECULAR BIOTECHNOLOGY, TOTOWA, NJ, US, vol. 19, no. 2, October 2001 (2001-10-01), pages 153 - 168, XP001055252, ISSN: 1073-6085 *
VALLE E ET AL: "Infliximab", EXPERT OPINION ON PHARMACOTHERAPY, ASHLEY, LONDON,, GB, vol. 2, June 2001 (2001-06-01), pages 1015 - 1025, XP002965315, ISSN: 1465-6566 *
WILLIAMS R O ET AL: "Combination therapy with DMARDs and biological agents in collagen-induced arthritis.", CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. ITALY 1999 NOV-DEC, vol. 17, no. 6 Suppl 18, November 1999 (1999-11-01), pages S115 - S120, XP009017873, ISSN: 0392-856X *
WOLDA S L: "PDE4 INHIBITORS AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE", EMERGING DRUGS, ASHLEY PUBLICATIONS, LONDON, GB, vol. 5, no. 3, 2000, pages 309 - 319, XP008016335, ISSN: 1361-9195 *

Also Published As

Publication number Publication date
WO2004098578A2 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
TNSN05265A1 (en) Composition comprising a pde4 inhibitor and a pde5 inhibitor
WO2005019190A3 (en) (4 -amino -1,2, 5-oxadiazol-4-yl) -hetξroaromatic compounds useful as protein kinase inhibitors
WO2004046120A3 (en) Diaminotriazoles useful as inhibitors of protein kinases
WO2005056547A3 (en) Quinoxalines useful as inhibitors of protein kinases
WO2005103050A3 (en) Azaindoles useful as inhibitors of rock and other protein kinases
MXPA04005790A (en) Compounds and uses thereof for decreasing activity of hormone-sensitive lipase.
WO2004087698A3 (en) Thiazoles useful as inhibitors of protein kinases
ES2195785A1 (en) Pyridazin-3(2h)-one derivatives as pde4 inhibitors
ATE466580T1 (en) AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITORS
ATE468336T1 (en) AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITORS
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
MY140872A (en) 5,7-diaminopyrazolo[4,3-d]pyrimidines with pde-5 inhibitory activity, compositions containing such derivatives and the use of such derivatives in the treatment of hypertension and other disorders
WO2003024392A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2005000298A3 (en) 5-membered heterocycle-based p-38 inhibitors
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
MX2007014619A (en) Pyrrolopyridines useful as inhibitors of protein kinase.
WO2003088808A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
AU4327300A (en) Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension
CA2462572A1 (en) Tetracycline derivatives and methods of use thereof
WO2006110760A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2002060386A3 (en) METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase